Aprepitant relieves chemotherapy-induced inappetance in colorectal cancer patients in the acute phase of mod-erate emetogenic chemotherapy: An observational study based on self-report diaries

Creators Kaneko Tadashi

Creators Furuya Takumi

Creators Fujimoto Takuya

Creators Kamimura Yoshio

Creators Takemoto Norikazu

Creators Hayashi Hideto

Creators Yahara Noboru

Creators Inoue Takeshi

Creators Saeki Toshihiro

Creators Hayashi Hiroto

Background: The novel drugs aprepitant (APR) and palonosetron are rec- ommended for the treatment of chemotherapy-induced nausea and vomiting. Here, we assessed the effects of these antiemetics using a self-report diary.Methods: This was a retrospective observational study based on data from 87 pa- tients spectively collected in 222 self-report diaries. We assessed the effect of vomiting and nausea on the patients'quality-of-life, and food and water intake. A“no event”was treated as a favorable outcome. We compared the rates of no event be-tween the first course of chemotherapy and subsequent courses, as well as among the different emetogenic risks and post-chemotherapy phases. We also studied the effect of APR in a subgroup of colorectal cancer patients receiving moderate emetogenic chemotherapy.Results: Nearly 90% of patients reported that the vomiting and nausea did not af- fect their quality-of-life

[ISSN]0513-1812

[NCID]AA00594272